Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China

Guangzhou University of Chinese Medicine

Status: Completed

Conditions: Unresectable Hepatocellular Carcinoma

Treatments: Drug: Chinese Herbal Medicine

Study type: Observational

Funder types: Other

Identifiers

NCT06315101

K-2023-092

Details and patient eligibility

About

This study aims to assess the effectiveness and safety of lenvatinib plus Chinese Herbal Medicine (CHM) for patients with uHCC in China.

Full description

Liver resection is one of the most important treatments for hepatocellular carcinoma (HCC). However, only a minority of patients have the opportunity to undergo surgery. The development of systemic therapy has dramatically changed the management of unresectable HCC (uHCC). And lenvatinib garners a recommendation as the primary treatment for uHCC. Many patients with uHCC in Asian countries seek complementary and alternative therapies with traditional Chinese medicine (TCM). However, the impact of lenvatinib combined with CHM on uHCC patients remains unclear. In this study, we conducted a retrospective cohort study to assess the effectiveness and safety of lenvatinib plus CHM for patients with uHCC in China.

Enrollment: 142 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• at least 18 years old
• histologically confirmed HCC unsuitable for resection
• lenvatinib as first- or second-line therapy

Exclusion criteria

• patients with other primary tumors
• patients who had only one visit record and were lost to follow-up or refused follow-up
• patients with any other factors affecting study data collection

Trial design

142 participants in 1 patient group

Lenvatinib combined with Chinese Herbal Medicine

Treatment:

Drug: Chinese Herbal Medicine